1.2 Antidepressants
Short Description
Antidepressants...
Description
Psychiatry 3
Dr. familar Antidepressants LEGENDS: IMPORTANT SIDENOTES 2 General Classifications of Antidepressants: • Cyclic Antidepressants – most commonly used in practice • Monoamine Oxidase Inhibitors PHARMACOLOGIC CLASS DRUG CYCLIC ANTIDEPRESSANTS Selective Serotonin Citalopram, Fluoxetine, Reuptake Inhibitors (SSRI) Paroxetine, Escitalopram, Fluvoxamine, Sertraline Norepinephrine Dopamine Bupropion Reuptake Inhibitor (NDRI) Selective Serotonin- Venlafaxine, Norepinephrine Reuptake Desvenlafaxine, Duloxetine Inhibitor (SNRI) Serotonin-2 Trazodone, Nefazodone Agonist/Serotonin Reuptake Inhibitor (SARI) Serotonin-1A Agonist/ Vilazodone Serotonin Reuptake Inhibitor Noradrenergic/Specific Mirtazapine Serotonergic Agent (NaSSA) Nonselective Cyclic Agents Desipramine, Amitriptyline, (Mixed Reuptake Nortriptyline, Imipramine Inhibitor/Receptor Blockers) MONOAMINE OXIDASE INHIBITORS Reversible MAO-A Inhibitor Moclobemide (RIMA) Irreversible MAO (A & B Phenelzine, inhibitors) (MAOIs) Tranylcypromine, Maprotiline Irreversible MAO-B Inhibitor Selegiline Common MOA: reuptake inhibition of Serotonin Leads to accumulation of serotonin -> SEROTONIN SYNDROME The specificity of the cyclic antidepressants’ reuptake of neurotransmitters somehow determines each drug’s spectrum of activity and adverse effects. Therapeutic Effects of Antidepressants • Elevated mood – most important effect • Improved sleep & appetite • Better memory (for pseudodementia in MDD) • Increased physical activity (for anhedonia, bradykinesia, hypokinisia in MDD) • Improved clarity of thinking • Decreased feelings of guilt, worthlessness, helplessness & inadequacy • Decrease in delusional preoccupation & ambivalence If it is MDD with psychotic features (i.e., with delusions of grandeur or paranoia), give antidepressants + antipsychotics Overview • In general, all antidepressants are equally efficacious at reducing the symptoms of depression •
Transcribed by: orquia, pat
1.2
•
•
•
•
Some antidepressants may apparently produce restlessness or psychomotor agitation before any improvement in depressive symptom is seen In children, adolescents and adults younger than age 24, a small (2-3%) risk of suicidal ideation or hostility may be present in some who take antidepressants Antidepressants from different classes may be combined if partial response or refractory cases are seen, but caution against serotonin syndrome resulting from drug interactions Tolerance to different antidepressants is seen in 10- 20% of patients in spite of compliance to treatment probably because of CNS adaptation, unrecognized rapid cycling or increase in severity of disorder.
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) Chemical class Generic name Trade Dosage name forms & strength s Phthalene Citalopram Celexa Tab/cap derivative 10, 20, 30, 40 mg Oral disintegr ating tab Oral solution Escitalopram Lexapro Tab/cap (most common 5, 10, 20 DOC for MDD) mg Oral solution Bicyclic Fluoxetine Prozac Capsule 10, 20, 40 mg Oral solution Fluoxetine/Olan Symbya Caps zapine x 25/3, 6, (Combination for 12 mg MDD with Caps psychotic 50/6, 12 features) mg Monocyclic Fluvoxamine Luvox Tabs 25, 50, 100 mg Phenylpiperidine Paroxetine Paxil Tabs 10, 20, 30, 40 mg Oral suspensi on Controlle d-release tab Tetrahydronaphthyl Sertraline Zoloft Cap/tab methylamine 25, 50,
Psychiatry 3
topic 100, 150, 200 mg Oral solution
All are in oral forms. SSRI Indications • Mood Disorders Ø MDD Ø MDD, recurrent, prophylaxis Ø Depression in bipolar I & treatment-resistant depression Ø Premenstrual dysphoric disorder Ø Dysthymia Ø Atypical depression Ø MDD in medical or other psychiatric disorders Ø Postpartum depression • Eating Disorders Ø Bulimia nervosa Ø Binge-eating disorder • Anxiety & Related Disorders Ø Panic disorder with or without agoraphobia Ø Social phobia Ø GAD Ø OCD Ø PTSD • Others Ø Pain management Ø Trichotillomania Ø Premature ejaculation Ø Body dysmorphic disorder Ø Schizophrenia, negative symptoms Ø Tardive dyskinesia Currently approved indications of SSRIs in US/Canada Disor Fluo Fluvo Paro Sertr Cital Escital der xetin xamin xetin aline opra opram e e e m MDD A/P - A A A A GAD - - A - - A OCD A/P A/P A A/P - A Panic A - A A - - disord er PTSD - - A A - - Social A - A A - - anxiet y disord er Bulimi A - - A - - a nervo sa Prem A - A A - - entru al Dysp horic Dso. Pediatric indications for: MDD - Fluoxetine OCD – Fluoxetine, Fluvoxamine, Sertraline
Transcribed by: orquia, pat
Mechanism of Action of SSRIs • Exact MOA is unknown • Inhibition of serotonin reuptake • Increased concentration of serotonin in the synapse • Downregulation of postsynaptic receptors Some SSRIs can also affect other neurotransmitters SSRI Other actions Citalopram & Most selective serotonin Escitalopram reuptake inhibitor Fluoxetine Weakly inhibits norepinephrine reuptake and binds to 5-HT2c receptors Sertraline Weakly inhibits norepinephrine & dopamine reuptake Paroxetine Significant anticholinergic activity at higher doses Pharmacokinetics of SSRIs • Absorbed relatively slowly but completely • Time to peak plasma concentration 3-8 hours • Undergo little first-pass effect • Highly bound to plasma protein and may even displace other drugs from protein binding but this is not clinically significant: FLUOXETINE, PAROXETINE, SERTRALINE • Metabolism primarily by the liver Ø All affect CYP450 and will affect metabolism of other drugs metabolized by this system Ø Least: CITALOPRAM and ESCITALOPRAM Ø Clearance of ALL SSRIs is reduced in patients with cirrhosis • FLUOXETINE and PAROXETINE decrease their own metabolism • FLUOXETINE, as well as its active metabolite, NORFLUOXETINE, have the longest half-lives (70 and 330 hours, resp.) Ø Peak plasma concentration of SERTRALINE is 30% higher when taken with food, as first pass metabolism is reduced • The most important drug-to-drug interactions involving the SSRIs occur as a result of inhibition or slowing by the SSRI of the metabolism of co- administered medications. Drug Characteristi Interaction Thro c with ugh Fluvoxamine Most Theophylline CYP notorious – 1A2 marked effect Clozapine CYP on several 1A2 CYP enzymes Alprazolam/Clo CYP nazepam 3A4 Fluoxetine & Significant Opiates such CYP Paroxetine effects as codeine & 2D6 hydrocodone by blocking conversion into their active forms Sertraline/ Least likely Citalopram/ for Escitalopram interaction
Psychiatry 3
topic
Drug
Bioavaila bility (%)
Prot ein bindi ng (%)
Elimina tion half-life (%)
Therap eutic dose range (mg)
80
Pea k plas ma level (%) 4
Citalopr am Escitalo pram Fluoxeti ne
80
23-45
10-40
80
54
4-5
27-32
10-20
72-85
94
4-8
10-80
60
2.5-4
>90
77- 80 95
24-144 (parent) 200- 330 (metab olite) 9-28
Fluvoxa mine Paroxeti ne Sertralin e
5.2
3-65
10-60
70
96
6
22-36 (parent) 62-104 (metab olite)
50-200
50-300
Onset & Duration of Action of SSRIs • Long acting Ø Can be given in single daily dose, usually in morning Ø Fluvoxamine and sertraline may cause sedation and may have to be given at night • Adequate clinical activity and saturation of the transporters Ø Most patients with depression respond to the initial dose Ø As a rule, higher dosages do not increase antidepressant effect but may increase the risk of adverse effects • Therapeutic effect seen in about 28 days but some may respond sooner • Tolerance to effects may be seen after months of treatment -> may lead to serotonin syndrome Adverse Effects of SSRIs • Incidence may be greater in the early days of treatment • Patients may adapt to them over time • If there is intake of a previous drug, may have to rule out withdrawal from that drug • CNS EFFECTS: Ø Headache is common § From FLUOXETINE mainly Ø Or a worsening of migraines § Generally effective prophylaxis for migraine & tension headache Ø Seizure episodes in those previously diagnosed § More frequent at the highest doses of the drug Ø Sedation or wakefulness § Improved sleep is the major effect but 25% report trouble sleeping or excessive sleepiness
Transcribed by: orquia, pat
Drug Effect on sleep Fluoxetine Insomnia Sertraline/Fluvoxamine Insomnia Somnolence Citalopram/Paroxetine Somnolence Escitalopram More likely insomnia • Case reports of cognitive impairment (short-term memory and attention affected) Ø Rarely tremor, EPS, and fine tremor • Anticholinergic effects Ø Mild dose-dependent dry mouth, constipation and sedation: PAROXETINE • Hematologic effects Ø Easy bruising, excess or prolonged bleeding without reduced platelet count Ø Caution with concomitant use of aspirin and NSAIDs • Sexual dysfunction Ø Most common side effect caused by all SSRIs, associated with long-term treatment Ø Result of increased serotonergic transmission through 5-HT2c receptor that results in reduced dopaminergic transmission and acetylcholine blockade Ø Affects all phases of sexual cycle Ø Reducing dose may help in some, Sildenafil has helped some, too • GI effects Ø Very common, resulting from activation of 5-HT2 receptors Ø Nausea, vomiting, diarrhea, anorexia, flatulence, and dyspepsia Ø Most severe symptoms are caused by SERTRALINE & FLUVOXAMINE Ø Up to one-third of patients may gain weight that happens gradually and is resistant to diet and exercise Ø Most weight gain is caused by PAROXETINE • Glucose disturbance Ø Acute decrease in glucose, so caution to diabetics Ø Long-term use may increase glucose levels • CV effects Ø All SSRIs can lengthen QT interval and cause QT syndrome even in the healthy, when taken in overdose especially CITALOPRAM § Poses the greatest risk § Dose should not exceed 40 mg/day or 20 mg/day for those over 45, with liver failure, if combined with CYP2C19 inhibitors or if taking Cimetidine § Do not give to those with congenital long QT syndrome § Monitor ECG and serum electrolytes and correct abnormal levels before prescribing • Serotonin syndrome Ø Serious and possibly fatal syndrome of serotonin overstimulation Ø With concurrent use of SSRI and MAOI or lithium or L-tryptophan
Psychiatry 3
•
•
Ø Symptoms appear in the following order, till it worsens: § Diarrhea § Restlessness § Extreme agitation, hyperreflexia & autonomic instability with fluctuation in vital signs § Myoclonus, seizures, hyperthermia, uncontrollable shivering, and rigidity § Delirium, coma, status epilepticus, cardiovascular collapse, and death Withdrawal Ø Abrupt discontinuation of an SSRI with a shorter half-life such as Paroxetine or Fluvoxamine may lead to dizziness, weakness, nausea, headache, rebound depression, anxiety, insomnia, poor concentration, upper respiratory symptoms, paresthesias, and migraine-like symptoms Ø May occur only after at least 6 weeks of treatment, and disappears in 3 weeks spontaneously Endocrine and allergic reactions Ø Increased prolactin levels caused by SSRIs can produce galactorrhea in both men and women Ø Rashes in some patients may generalize to involve the pulmonary system, resulting in rare fibrotic damage and dyspnea Ø Discontinue if with drug-related rashes
In children & adolescents – no SSRI is approved for clinical use in Canada Drug MDD OCD Fluoxetine Age 8-17 Age 7-17 Fluvoxamine No data >age 7 Sertraline Efficacy not >age 6 demonstrated in clinical trials Paroxetine Efficacy not ? demonstrated in clinical trials Citalopram Efficacy not ? demonstrated in clinical trials Escitalopram No data ? • SSRIs have been associated with increased suicidal ideation, hostility and psychomotor agitation in clinical trials involving children, adolescents and young adults, which was not seen in those aged 24- 65 • They may even be protective for those over 65 • Monitor all patients for worsening of depression and suicidal thinking In the Elderly • Initiate lower dose and increase more slowly • Elderly may take longer to respond and may need trials of at least 12 weeks before treatment response is noted. • Higher doses of fluoxetine have been associated with delirium • SSRIs generally have low risk of CNS, anticholinergic and cardiovascular effects
Transcribed by: orquia, pat
topic SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI) Chemical Drug name Trade Dosage class name forms & strengths Bicyclic Venlafaxine Effexor Tab 25, agent 37.5, 50, 75, 100 mg Effexor XR Extended release tab/cap 37.5, 75, 150, 225 mg Duloxetine Cymbalta Delayed- release cap 20, 30, 60 mg Desvenlafaxine Pristiq Extended release tab 50, 100 mg • Potent reuptake inhibitors of serotonin and norepinephrine • Venlafaxine inhibits norepinephrine reuptake at doses above 150 mg • Duloxetine has equal affinity to both serotonin and NE receptors Indications of SNRIs Venlafaxine Duloxetine Desvenlafaxine MDD √ √ √ GAD √ √ - Social √ - - Phobia Panic √ - - Disorder • Other indications Ø Neuropathic pain Ø Pain from fibromyalgia Ø Chronic musculoskeletal pain Ø Pain due to osteoarthritis Ø Bipolar disorder: depressed phase Ø Treatment resistant depression, dysthymia, postpartum depression and melancholic depression Ø OCD Dosing and Pharmacokinetics Drug Thera Bioava Pro Pea Elimi Metab peuti ilability tein k natio olizin c (%) bin pla n g dose din sm half- enzym (mg) g a life es (%) lev el (%) Venlafa 75- 11 27 2 5-7 1D6, xine 375 (pare 3A4, nt) 2C9, 8-13 2C19 (meta bolite) Desven 50- 80 30 7.5 11 UGT lafaxine 100 1A4
Psychiatry 3 Duloxet 60- 70 25 6 6-19 1A2, ine 120 2D6 • Desvenlafaxine is the major active metabolite of venlafaxine which is not metabolized by CYP2D6. • This may result in its reduced risk of interaction with other drugs. • Venlafaxine & desvenlafaxine are well absorbed from GIT and food has no effect on absorption • Duloxetine may or may not be given with meals • Therapeutic effect typically seen after 28 days or sooner in some • Clinical trials among children have shown associated increased suicidal ideation, and psychomotor agitation;; close monitoring needed if depression worsens and suicidal thoughts are noted.
Side Effects of SNRIs • Generally dose-dependent • Safety and tolerability of Venlafaxine is similar to the SSRIs • Nausea is most common;; headache, too • Other common ones include dry mouth, dizziness, somnolence, constipation and sweating • Rise in BP noted with higher doses of venlafaxine;; duloxetine, too • For those with diabetes or are high risks, increase in blood sugar and hemoglobin A1C levels are noted with long-term treatment • Hepatic problems may ensue with duloxetine use, so avoid giving to those who abuse alcohol • Fatal overdoses have been documented with venlafaxine in combination with alcohol, other drugs or both • Avoid duloxetine in those with severe renal insufficiency and liver disease • Do not use SNRI in those with uncontrolled hypertension • Serotonin syndrome may occur • May induce mania in those with bipolar disorder Discontinuation syndrome manifesting as Dizziness Dry mouth Sweating Incoordination Lethargy Diarrhea Chills Insomnia Nausea Headache Malaise Nervousness Vomiting Fever Anorexia Sensory disturbances • These medications should be withdrawn gradually over several weeks after prolonged use!!! NORADRENERGIC/SPECIFIC SEROTONERGIC ANTIDEPRESSANT (NaSSA) Chemical Drug name Trade Dosage class name form & strengths Tetracyclic Mirtazapine Remeron Tab 7.5, 15, agent 30, 45 mg Remeron Oral Soltab disintegrating tab 15, 30, 45 mg Indications of NaSSA • MDD (with or without comorbid anxiety)
Transcribed by: orquia, pat
topic • • •
Panic disorder, GAD, social anxiety disorder Sexual dysfunction, SSRI-induced Serotonin syndrome
Mechanism of Action of NaSSA • Antagonism of central presynaptic α2-adrenergic receptors – increased firing of norepinephrine and serotonin neurons • Blockade of post synaptic serotonin 5 HT2 and 5 HT2 receptors – decrease anxiety, relieve insomnia, and stimulate appetite • Potent antagonism of H1 receptors and moderate antagonism of α1 adrenergic and muscarinic cholinergic receptors • Reduces sleep latency and prolongs sleep duration due to H1 and 5-HT2A/C blockade • This may be helpful in treating depression with prominent insomnia or agitation • Has mild anxiolytic effect at low doses • Increases both norepinephrine and serotonin through a mechanism other than reuptake blockade (as in the case of SSRI and TCA), or monoamine oxidase inhibition (as in the case of phenelzine or moclobemide) Pharmacologic Actions of NaSSA • Orally administered • Rapidly and completely absorbed • Half-life of about 20-40 hours • Peak concentration in 2 hours of ingestion • Steady state after 6 days • Plasma clearance impaired by liver disease and renal disease • Plasma clearance slowed in the elderly • Food slightly decreases absorption rate • Protein binding about 85% • Extensively metabolized by CYP1A2, 2D6, and 3A4 • Therapeutic effect seen after 28 days but effects on sleep and appetite are seen sooner • Remeron SolTabs dissolve on tongue within 30 seconds and can be swallowed with or without water, chewed or allowed to dissolve Side effects of NaSSA Side effect Percentage affected Somnolence 54 Dry mouth 25 Increased appetite 17 Constipation 13 Weight gain 12 Dizziness 7 Myalgias 5 Disturbing dreams 4 • Hypotension, hypertension, tachycardia and palpitations are rare • No significant ECG changes • Sexual dysfunction occurs occasionally • Risk increased with age, higher doses and concomitant medications • Monitor all patients for worsening depression and suicidal thoughts with treatment • Low liability for toxicity in overdose if taken alone • May induce manic reactions in those with bipolar disorder
Psychiatry 3 • •
Early data suggests no teratogenic effects in humans Higher rate of spontaneous abortions and preterm births reported Secreted into breast milk in low concentrations
• Discontinuation syndrome • Withdraw gradually after prolonged use because of manifestations of dizziness, lethargy, nausea, vomiting, diarrhea, headache, fever, sweating, chills, incoordination, and others NOREPINEPHRINE DOPAMINE REUPTAKE INHIBITOR (NDRI) Chemical Drug name Trade Dosage class name form & strength Monocyclic Bupropion Wellbutrin Tabs 75, agent 100 mg (aminoketone) Wellbutrin Sustained SR release tab 100, 150, 200 mg Wellbutrin Extended XL release tab 150, 300, 450 mg Indications of NDRI • MDD • Prophylaxis for recurrent MDD • Bipolar disorder, depressed phase • Smoking cessation (Zyban, extended-release tablet) • Seasonal affective disorder Mechanism of action of NDRI • Inhibits reuptake of primarily norepinephrine and to a lesser extent, dopamine, into the presynaptic neurons • Hydroxybupropion, the major metabolite, is 10- to 20-fold higher than bupropion and blocks only norepinephrine reuptake • May have lower switch rate to mania or hypomania than other antidepressants • May enhance energy and motivation early in treatment due to effects on norepinephrine and dopamine • Reported to improve neurocognitive function in patients with depression • Does not potentiate the sedative effects of alcohol • Least likely of all antidepressants to impair sexual functioning Pharmacologic action of NDRI • Rapid absorption: peak concentration in 3 hours • Protein binding 80-85% • Metabolism primarily by liver, through CYP2B6 • Both bupropion and hydroxybupropion inhibit CYP2D6 isoenzyme • Elimination half-life 11-14 hours;; longer with chronic dosing • Decreased clearance reported in elderly • Therapeutic effect usually after 28 days • Caution with use in those with hepatic and renal impairment • May lower seizure threshold
Transcribed by: orquia, pat
topic •
Contraindicated in patients with history of anorexia or bulimia, undergoing alcohol or benzodiazepine withdrawal
Adverse effects of NDRI • Primarily a result of effects on dopamine and norepinephrine • Insomnia, headache, tremor, nausea, dry mouth are most common • Vivid dreams and nightmares • Agitation, anxiety, irritability • Can exacerbate psychotic symptoms • Reported to exacerbate symptoms of OCD • Seizures with abrupt dose increases or high daily dose above 450 mg • Most notable in the absence of significant drug- induced orthostatic hypotension, weight gain, daytime drowsiness and anticholinergic effects SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (SARI) Chemical class Drug name Trade Dosage name form & strength Phenylpiperidine Nefazodone Serzone Tabs 50, 100, 150, 200, 250 mg Triazolopyridine Trazodone Desyrel Tabs 50, 68.25, 100, 150, 300 mg Oleptro Extended release tab 150, 300 mg Indications of SARI • MDD • MDD, recurrent, prophylaxis • Bipolar disorder, depressed phase • Agoraphobia with panic disorder • Dysthymia • Social phobia • PTSD Mechanism of action of SARI • Exact MOA is unknown • Cause downregulation of β-adrenergic neurons • Trazodone inhibits reuptake of serotonin and induces changes in 5-HT presynaptic receptor adrenoceptors • Nefazodone inhibits neuronal reuptake of serotonin and norepinephrine Adverse effects of SARI • CNS: Result of antagonism at histamine H1 receptors and α1 adrenoceptors • Occur frequently • Drowsiness: most common • Weakness, lethargy, fatigue • Anticholinergic: Result of antagonism by muscarinic receptors • Dry eyes, blurred vision, constipation, and dry mouth
Psychiatry 3 •
• • • • • • • •
CV: Result of antagosim at α1 adrenoreceptors, muscarinic, 5-HT2AC and H1 receptors, and inhibition of sodium fast channels More common in elderly Dizziness, orthostatic hypotension, and syncope Bradycardia: Nefazodone Exacerbate transient ischemic attacks GI: Result of inhibition of 5-HT uptake and M1 receptor antagonism Peculiar taste, glossitis Beware of discontinuation syndrome Use caution in combination with drugs prolonging QT interval
------------------------------------------------------------------------------------ SHORT QUIZ RECALLS (NON-VERBATIM) CASE A: Ate gurl suffers from insomnia and MDD, unable to take care of her child and was fired from her job because she’s no longer productive. DOC, justification and what would you advise the patient/cautionary use: a. Paroxetine (SSRI) Justification: AE includes somnolence, so it would normalize the sleep-‐wake cycle of the patient Caution: Take note of her diet because it causes weight gain and she may feel anti-‐cholinergic AEs (dry mouth, constipation, etc.) b. Citalopram (SSRI) Justification: SAME Caution: may cause CV problems (QT prolongation) c. Mirtazapine (NaSSA) • Justification: reduces sleep latency and prolongs sleep duration due to H1 and 5-‐HT2A/C blockade, SAME Caution: may cause dry mouth, increased appetite, etc. CASE B: Manong suffers from MDD and has a history of hypertension and angina attacks. DOC: ANY DRUG EXCEPT CITALOPRAM because it causes CV problems (QT prolongation). Don’t know the details of the other cases. CASE C: Surgeon yada yada with insomnia. DOC, justification: PLEASE FOLLOW CASE A ANSWERS. CASE D: Preggers near term yada yada. According to Doc Familiar, ANY DRUG WILL DO. Answer if patient is not yet term: ANY DRUG EXCEPT MIRTAZAPINE (NaSSA) because it causes spontaneous abortion and preterm delivery.
Transcribed by: orquia, pat
topic
View more...
Comments
